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Abstract Objective: Early clinical response to antide-
pressant treatment is an important therapeutic goal,
considering the psychological, social and economic
consequences of depression. The aim of the present
study was to investigate the relationship between the
time course of response and the concentration of ven-
lafaxine (V), its active metabolite O-desmethylvenlafax-
ine (ODV) and enantiomeric ratios V(+)/V()) and
ODV(+)/ODV()).
Methods: Depressed inpatients (n=35) received V orally
at a ﬁxed 300 mg daily dose. Accepted comedication in-
cluded clorazepate (maximum 60 mg/day), zopiclone
(maximum 15 mg/day) and low-dose trazodone (maxi-
mum200 mg/day). Severity of depressionwas assessed on
days 0, 4, 7, 11, 14, 21 and 28 (Montgomery and A˚sberg
Depression Rating Scale). Blood samples were taken on
day 14 and day 28 and submitted to stereoselective
determination. All measurements reﬂected trough steady-
state values. First, pattern analysis was used to provide a
categorical perspective of clinical response (50%
improvement from baseline depression score). Patients
displaying non-response, transient response, early per-
sistent response and delayed persistent response were
compared with respect to racemic concentrations and
enantiomeric ratios. Second, in a dimensional perspective,
mixed-eﬀects modelling was used to analyse severity of
depression versus time curves with respect to the possible
inﬂuence of concentrations and enantiomeric ratios.
Results: Comparison of patients with and without per-
sistent response did not reveal any signiﬁcant diﬀerence
for V, ODV, V+ODV plasma levels or enantiomeric
ratios. Persistent responsewas signiﬁcantly associated with
less frequent pre-study antidepressantmedication and less
frequent comedication with zopiclone (day 14) and clo-
razepate (day 28) during the study.Focus onpatientswith
persistent response (n=19, 54.3%) indicated that early
response, ﬁrst observed before day 14, was associated
with signiﬁcantly higher V+ODV concentration than
delayed response (median 725 ng/ml versus 554 ng/ml,
P=0.023). No diﬀerence was found for pre-study medi-
cation or comedication during the study. Shorter time to
onset of response was signiﬁcantly associated with lower
V(+)/V()) enantiomeric ratio (rs=0.48, P<0.05).
Mixed-eﬀectsmodelling of depression severity versus time
curves in patients with persistent response conﬁrmed that
either higher V+ODV plasma level or lower V(+)/V())
ratio were signiﬁcantly associated with more rapid
decrease of depression score (likelihood ratio tests,
P=0.012 and P=0.046, respectively).
Conclusion: Considering its modest sample size, natu-
ralistic design and limited observation period, the present
study provided preliminary indication that earlier clinical
response may occur with higher V+ODV plasma level,
extending previous dose-response studies. The hypothesis
was also raised that exposure to a more potent norad-
renergic therapeutic moiety, as reﬂected by a lower V(+)/
V()) ratio, may be relevant to early improvement of
depression.
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Introduction
The antidepressant venlafaxine (V) is characterised by a
positive dose-eﬀect relationship both for clinical
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response and occurrence of adverse reactions [1, 2, 3]. In
addition, emerging evidence indicates that earlier
response may be achieved with a higher daily dose [4, 5].
Onset of response to antidepressant treatment has been
the focus of much debate in recent years, earlier clinical
response being not only beneﬁcial to the patient and the
family, but also associated with decreased societal and
economic burden [6, 7, 8]. V, among other drugs, has
been postulated as a fast-onset antidepressant, based on
diﬀerent lines of evidence. Preclinical studies have sug-
gested rapid onset of action to be associated with rapid
desensitisation of the beta-adrenergic receptor system
[9]. Placebo-controlled studies have shown signiﬁcantly
greater clinical improvement with V than with placebo
as early as week 1 [6, 10, 11]. In comparative studies,
faster onset of response was documented with V than
with imipramine [12] or serotonin (5-HT)-speciﬁc
reuptake inhibitors [13]. Nevertheless, earlier onset of
response when compared with alternative treatment
options has not always been observed [14, 15], possibly
because of methodological diﬀerences between studies.
With speed of action becoming a central issue for
pharmaceutical companies, speciﬁc methodological rec-
ommendations have been proposed for studies aimed at
estimating onset of response [16, 17]. According to Leon
et al. [16], key features include: (1) a prospective,
operational deﬁnition of early onset of response; (2)
frequent assessments of depression severity during the
early phase of treatment; (3) strategies to minimise bias
and heterogeneity of response, e.g. adequate dosage
achieved within a short period of time and (4) statistical
approaches capable of capturing the dynamic nature of
symptomatic change.
The pharmacology of putative early onset antide-
pressants has recently been reviewed [18, 19], with
accumulating data suggesting a possible association be-
tween early response and a dual mechanism of action on
serotonin (5-HT) and noradrenaline (NA) reuptake
inhibition. Over V clinically relevant dose range, 5-HT
and NA uptake inhibition are sequentially engaged [20],
leading to the hypothesis of the NA system being crucial
in faster onset of response at higher dose. Pharmaco-
logical properties of V enantiomers may also be invoked,
V(+) selectively inhibiting 5-HT reuptake and V())
displaying both noradrenergic and serotonergic activity
[21]. Due to stereoselective disposition in humans [22]
and large inter-individual pharmacokinetic variability
[23], diﬀerent patients may be exposed to diﬀerent
pharmacological proﬁles at a given dose. Despite
potential clinical relevance, the concentration–response
relationship of V has been little investigated and has
been restricted to racemic concentrations of parent
compound and its active metabolite, O-des-
methylvenlafaxine (ODV) [24, 25, 26].
The present investigation was part of a study on
lithium augmentation of V therapy in hospitalised
patients with depression [27]. Its general objective was to
determine whether chiral determination of plasma con-
centration might contribute to a better understanding of
pharmacokinetic and pharmacodynamic variability in
patients. Pharmacokinetic variability has been the focus
of an earlier publication in this journal [23]. In the
present article, the concentration–response relationship
was analysed through two diﬀerent statistical
approaches, taking into account enantiomers of V and
ODV. First, pattern analysis [28] proceeded by classiﬁ-
cation of patients according to whether onset of clinical
response was early (<2 weeks) or delayed and whether
response was persistent or transient. Group comparison
with respect to plasma levels, enantiomeric ratios and
comedication was then performed. Second, mixed-eﬀects
models [29], conceptually similar to models used in
population pharmacokinetics, were used to describe the
time course of clinical improvement and its relationship
to concentration, taking into account heterogeneity of
proﬁles among patients.
Materials and methods
Patients
The present study included 35 inpatients who participated in an
open ﬁxed-dose study of V, with low-dose trazodone augmentation
for severe and persistent insomnia and lithium augmentation for
non-responders at week 4 [27]. Inclusion criteria were age range
18–65 years, diagnosis of moderate or severe depressive episode
without psychotic symptoms (ICD-10 criteria [30]) and a score at
inclusion ‡25 on Montgomery and A˚sberg Depression Rating Scale
(MADRS [31]). Exclusion criteria were pregnancy, schizophrenia,
schizoaﬀective disorder, dependence syndrome, presence of a so-
matic illness that was a contraindication to the prescription of
venlafaxine, trazodone or lithium and previously documented
hypersensitivity to these drugs. Patients were also excluded if they
were receiving mood stabilising drugs at inclusion and if they were
non-responders to previous V treatment at a daily dose ‡225 mg.
Description of the patients is provided in Table 1. For the 14 pa-
tients with pre-study antidepressant medication, distribution of
drugs was as follows: citalopram (n=5), paroxetine (n=2),
sertraline (n=1), low-dose venlafaxine (n=2), trazodone (n=2),
nefazodone (n=1), moclobemide (n=1) and low-dose trimipr-
amine (n=1). No washout period was considered necessary in these
patients. When present at inclusion visit (n=5), antipsychotic
medication at a low to moderate dose was discontinued.
Protocol and informed consent form received approval from the
ethics committee of the Department of Psychiatry, Geneva
University Hospitals. After receiving a complete description of the
study and possible side eﬀects, each patient provided written
informed consent before being enrolled.
Treatment
After inclusion, patients were rapidly titrated to a 300-mg daily
dose of V, which remained constant from day 3 onward (150 mg
b.i.d.). Accepted psychotropic comedication included clorazepate
(maximum 60 mg/day), zopiclone (maximum 15 mg/day) and
trazodone, introduced at low-dose (maximum 200 mg/day) in case
of severe and persistent sleep disorder (MADRS sleep item ‡4 for
at least 1 week). The present study focused on data collected up to
day 28, i.e. before lithium was introduced in non-responders.
Psychotropic comedication during the study is documented in
Table 1. Comedication prescribed for somatic disorders was pres-
ent in 15, 18 and 20 patients on days 0, 14 and 28, respectively.
Most frequent classes of drugs were hormonal preparations (n=6–
7 patients), analgesic and anti-inﬂammatory products (n=5–8),
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laxatives (n=3–4) and medications for the cardiovascular system
(n=2–5).
Blood samples were taken on day 14 and day 28 for therapeutic
drug monitoring purpose. A majority of samples (80%) were
obtained at 14 h post-dose (range 12–16 h) and reﬂected trough
values, with usual intake times at 1800 hours and 0800 hours.
Because half-lives are about 4 h for V and 10 h for ODV [32], and
posology was kept constant from day 3 onward, patients were
considered at steady-state for parent compound and metabolite. All
patients had chiral determination of V and ODV.
As reported previously [23], inter-individual variability was
larger for the parent compound (77%) than for the metabolite
(33%) and the active moiety V+ODV (31%). Estimates for V(+)/
V()) and ODV(+)/ODV()) enantiomeric ratios were 47% and
70%, respectively. Intra-individual variability arising from
repeated measurements on day 14 and day 28 was below 20% for
V, ODV, V+ODV and enantiomeric ratios. The present article
focused on concentrations measured on day 14, postulated to
reﬂect exposure to drug treatment throughout the 4-week obser-
vation period.
Analytical method
In a ﬁrst stage, concentrations of V and ODV were determined by a
gas chromatography method with nitrogen-phosphorus detection
[23]. Within-day coeﬃcients of variation for V were 3.2% at
10 ng/ml, 2.8% at 100 ng/ml and 2.0% at 200 ng/ml. They were
7.2% at 10 ng/ml, 6.7% at 100 ng/ml and 6.5% at 400 ng/ml for
ODV. Between-day coeﬃcients of variation were 2.9% at 100
ng/ml for V and 2.8% at 300 ng/ml for ODV. In a second stage, a
validated stereoselective capillary electrophoresis method was used
for the determination of the enantiomeric concentrations from
which (+)/()) ratios were calculated [33]. After optimisation of the
method (including robustness), validation was carried out. In the
tested concentration range (25–500 ng/ml), correlation coeﬃcients
were superior to 0.996. Within-day and between-day accuracy and
precision were determined at three diﬀerent concentrations for each
enantiomer. For both analytes, within-day accuracies were superior
to 95%. Day-to-day accuracy, for serum-spiked samples at a
concentration of 50 ng/ml, was superior to 95.0% of the expected
value with precision (relative standard deviation) inferior to 15.0%.
At 250 ng/ml, day-to-day accuracies were superior to 97.0% with
precision inferior to 5.0%. At 500 ng/ml, accuracy did not diﬀer
more than 1.0% of expected values, with precision inferior to 6.0%.
Clinical assessments
Severity of depression over time was assessed through MADRS
total scores on days 0, 4, 7, 11, 14, 21 and 28. The MADRS
depression scale has demonstrated adequate inter-rater reliability,
validity and sensitivity to change in antidepressant clinical trials
[31, 34]. Information about adverse events was collected at same
time intervals on the basis of open questions.
Statistical analysis
Pattern analysis
Pattern analysis was introduced by Quitkin [28] with the aim of
diﬀerentiating drug-speciﬁc and non-speciﬁc placebo response in
individual patients. It has been used with success to assess onset of
clinical response [6, 11].
In the present study, clinical response was deﬁned as 50%
improvement from baseline MADRS score. This criterion has
strong precedence of use, and its clinical meaning is generally
recognised [35]. Response observed before day 14 was considered
as an early response, whereas response ﬁrst observed on day 14 or
later was considered as a delayed response. Response was further
categorised as persistent if all subsequent assessments up to day 28
qualiﬁed for response and as transient if at least one of these
evaluations did not meet the criterion for response. Patients were,
thus, classiﬁed into one of the following four categories: non-
response, transient response, early persistent response and delayed
persistent response. In patients displaying persistent response, time
to onset of response was deﬁned as the time of ﬁrst occurrence of
response. Group comparison proceeded through Fisher exact test
for categorical variables (e.g. comedication) and Mann-Whitney
U-test for continuous variables (e.g. concentration). Association
Table 1 Patient description
(n=35). ICD-10 International
Classiﬁcation of Diseases, 10th
revision [30], MADRS
Montgomery and A˚sberg
Depression Rating Scale [31]
Age (median, range) 44 22–60
Gender (n, %)
Males 14 40.0%
Females 21 60.0%
Psychiatric diagnosis according to ICD-10 criteria (n, %)
Depressive episode (F32) 20 57.1%
Recurrent depressive disorder (F33) 13 37.1%
Bipolar aﬀective disorder, current episode depression (F31) 2 5.7%
Speciﬁc or mixed personality disorder (F60–F61) 12 34.3%
Anxiety or obsessive–compulsive disorder (F40–F42) 7 20.0%
Baseline MADRS depression score (median, range) 38 25–52
Pre-study psychotropic medication (n, %)
Antidepressants 14 40.0%
Antipsychotics 5 14.3%
Benzodiazepines 30 85.7%
Other hypnotics 11 31.4%
Psychotropic comedication during the study (n, %)
Clorazepate Day 0 32 91.4%
Day 14 30 85.7%
Day 28 29 82.9%
Zopiclone Day 0 32 91.4%
Day 14 25 71.4%
Day 28 23 65.7%
Trazodone Day 0 1 2.9%
Day 14 6 17.1%
Day 28 14 40.0%
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between continuous variables was assessed through Spearman
rank-order correlation coeﬃcient (rS). Statistical signiﬁcance was
set at 0.05.
Mixed-eﬀects modelling
Mixed-eﬀect modelling for the analysis of depression severity ver-
sus time curves was ﬁrst introduced by Gibbons [29]. It was recently
recommended to capture the dynamic process of onset of clinical
improvement, while taking into account heterogeneity of individual
proﬁles [16].
In a ﬁrst stage, MADRS score yit of patient i at time t was
described by the following quadratic random-eﬀects model:
yit ¼ ai þ bit þ cit2 þ eit ð1Þ
where ai, bi and ci are intercept, slope and quadratic coeﬃcients for
subject i, respectively. Distributions of these individual parameters
are assumed multivariate normal, with mean values a, b, c corre-
sponding to population values and variance terms r2a; r
2
b; r
2
c
reﬂecting inter-individual variability. The residual error term it
describes diﬀerences between measured and predicted MADRS
scores, assumed to be normally distributed with mean 0 and vari-
ance r
2. Estimation of the 7-parameter model
a; b; c; r2a; r
2
b; r
2
c and r
2
c
 
was performed considering all data
together (N=133 data, n=19 patients). Bayesian post-hoc
estimates of individual parameters were also provided.
In a second stage, these post-hoc estimates were plotted against
potential covariables (e.g. concentration) in order to explore
whether they may inﬂuence the shape of depression severity versus
time curves. If a signiﬁcant trend was observed, the covariable was
included as a ﬁxed-eﬀect into the model, which was rewritten as
follows.
yit ¼ ai þ bi þ bXð Þt þ ci þ cXð Þt2 þ eit ð2Þ
where b and c are coeﬃcients describing the inﬂuence of covariate
X on slope and quadratic term, respectively. The inﬂuence of
concentration was assessed in terms of variation around median
value in the population. As candidate covariables generally dis-
played positively skewed distributions, they were log-transformed
in order to ensure that outlying values may not be unduly inﬂuent.
The full 9-parameter model was estimated considering all data
together.
The likelihood ratio test was used for comparison of models of
increasing complexity. To test whether including a covariable
would signiﬁcantly improve the goodness of ﬁt, twice the diﬀerence
of log-likelihoods was compared with the v2 distribution with two
degrees of freedom. Signiﬁcance level was at 0.05. Models were also
assessed with respect to standard errors of parameter estimates and
the following graphs: (1) observed and predicted depression scores
versus time; (2) residuals (i.e. observed-predicted scores) versus
time and versus prediction and (3) observed versus predicted
depression scores. Graphics were considered for both population
and individual post-hoc predictions. Descriptive statistics of
residuals were calculated at each time and per patient. Data
analysis was performed using SYSTAT 10 (Systat Software Inc.,
Richmond, CA, USA), which integrates the implementation of
mixed models as described by Hedeker and Gibbons [36].
Results
Response patterns and relationship with concentration
Figure 1 illustrates severity of depression versus time
data for individual patients and their distribution
according to patterns of non-response (n=8, 23%),
transient response (n=8, 23%), early persistent response
Fig. 1 Patterns of Montgomery
and A˚sberg Depression Rating
Scale depression score versus
time curves in 35 patients with
venlafaxine 300 mg/day.
Clinical response was deﬁned as
50% improvement from
baseline score. It was
considered as persistent if all
subsequent assessments met the
criterion for response and as
transient otherwise. Response
was labelled early and delayed if
ﬁrst observed before day 14 or
from day 14, respectively
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(n=11, 31%) and delayed persistent response (n=8,
23%). In keeping with the postulate that transient
response may not be clinically meaningful [35], a ﬁrst
series of comparisons focused on diﬀerences among
patients displaying persistent response and either
non-response or transient response to V therapy.
Groups did not statistically diﬀer with respect to gender,
age, diagnosis of personality disorder or anxiety disorder
nor MADRS depression score at inclusion. Pre-study
medication did not diﬀer, except for antidepressants,
which were less frequent in persistent response (21.1%
versus 62.5%, P=0.018). No statistical diﬀerence was
seen for V, ODV or total V+ODV concentration
(Table 2). Similarly, no diﬀerence was found for V(+)/
V()) and ODV(+)/ODV()) enantiomeric ratios. How-
ever, diﬀerences appeared with respect to zopiclone and
clorazepate, but not trazodone comedication during the
study. Zopiclone was signiﬁcantly less frequent in per-
sistent response on day 14 (52.6% versus 93.8%,
P=0.010), with a similar diﬀerence for clorazepate on
day 28 (68.4% versus 100.0%, P=0.022). Since these
comedications were prescribed in a large majority of
patients when entering the study (Table 1), and no dif-
ference between groups was present at that time, results
suggested more frequent discontinuation of zopiclone
and clorazepate in patients with persistent, clinically
meaningful response.
In agreement with the recommendation that analysis
of onset of response should focus on treatment
responders [37], a second series of comparisons con-
centrated on early versus delayed persistent response
(Table 2). Groups did not statistically diﬀer with
respect to age, gender, diagnosis of personality or
anxiety disorder, MADRS at inclusion nor pre-study
medication. Whereas no diﬀerence was observed for
racemic V and ODV concentrations, early response was
associated with signiﬁcantly higher V+ODV concen-
tration than delayed response (median concentrations
725 ng/ml and 554 ng/ml respectively, P=0.023).
Unlike for ODV, the enantiomeric ratio for V was
lower in early persistent response, but the diﬀerence
remained above statistical signiﬁcance (median values
0.88 and 1.40 respectively, P=0.083). Interestingly, of
seven patients with V(+)/V()) ratio <1 (range 0.41–
0.95), ﬁve (71.4%) simultaneously displayed total con-
centration >700 ng/ml. All were early responders to
treatment. No diﬀerence between groups was observed
for clorazepate, zopiclone or trazodone comedication
on either day 0, 14 or 28.
In patients with persistent response, median time to
onset of response was 11 days (range 4–21 days). Time
to onset displayed signiﬁcant positive correlation with
V(+)/V()) enantiomeric ratio (rs=0.48, P<0.05), but
not ODV(+)/ODV()) nor V, ODV and V+ODV con-
centrations. Early relative MADRS decrease, as seen on
day 7, was signiﬁcantly associated with higher V+ODV
concentration (rs=0.54, P<0.05) and lower V(+)/V())
ratio (rs=)0.58, P<0.05), but not V, ODV or
ODV(+)/ODV()) ratio. No association remained
signiﬁcant when considering ﬁnal MADRS decrease on
day 28.
Mixed-eﬀects modelling of depression severity
versus time curves
Mixed-eﬀects models were developed to further investi-
gate the potential role of concentration with respect to
depression severity versus time curves in patients with
persistent response, taking into account heterogeneity of
trends over time. Because MADRS depression score did
not start decreasing before week 1 or week 2 in some
patients (Fig. 1), a quadratic model was selected for the
time eﬀect. Table 3 provides a summary of the principal
models tested.
The simplest random-eﬀects model (model 1) allowed
to estimate mean intercept, slope and quadratic coeﬃ-
cient in the population. Early decrease of depression
score, estimated from average slope in the population,
was )2.2 MADRS points per day. The model also
Table 2 Response patterns and diﬀerences with respect to venlafaxine concentration on day 14. V venlafaxine, ODV O-des-
methylvenlafaxine, N.S. not signiﬁcant
Persistent response, no Persistent response, yes Persistent yes
versus no signa
Early versus
delayed signa
Non-response Transient
response
Early
(day<14)
Delayed
(day‡14)
(n=8) (n=8) (n=11) (n=8)
V+ODV (ng/ml) Median 719 576 725 554 N.S. 0.023
Range (466–819) (418–803) (458–1605) (202–988)
V (ng/ml) Median 192 160 214 146 N.S. N.S.
Range (37–496) (69–393) (74–1294) (27–320)
ODV (ng/ml) Median 475 351 589 385 N.S. N.S.
Range (298–569) (285–734) (209–772) (175–708)
V(+)/V()) Median 0.82 0.88 0.88 1.40 N.S. 0.083
Range (0.55–1.95) (0.41–2.28) (0.41–1.62) (0.95–1.94)
ODV(+)/ODV()) Median 1.12 0.98 0.93 0.96 N.S. N.S.
Range (0.76–1.95) (0.84–3.67) (0.70–16.42) (0.72–7.57)
aMann-Whitney U test
887
provided estimates of between-patient variability for
intercept, slope and quadratic term. Estimated vari-
ability for slope was 45.0%, with post-hoc estimates for
individual patients in a range )3.4 to 0 points per day.
Search for inﬂuent covariables proceeded through plots
of these individual slope estimates against V, ODV,
V+ODV concentrations, as well as V and ODV enan-
tiomeric ratios. As illustrated in Fig. 2, higher V+ODV
concentration and lower V(+)/V()) ratio were signiﬁ-
cantly associated with increasingly negative slope
(rS=)0.50, P<0.05 and rS=0.55, P<0.05, respec-
tively). When total concentration was entered into a
mixed-eﬀects model (model 2), goodness-of-ﬁt sig-
niﬁcantly improved (likelihood ratio test, P=0.012) and
inter-individual variability for slope decreased to 30.0%.
Total V+ODV concentration was, thus, conﬁrmed as a
signiﬁcant determinant of the slope of MADRS versus
time curves. Not unexpectedly, an opposite eﬀect was
observed for the quadratic term, which correlated neg-
atively with slope. Similarly, when V(+)/V()) ratio was
entered into the model (model 3), goodness-of-ﬁt im-
proved signiﬁcantly when compared with a model
without covariate (likelihood ratio test, P=0.046). No
further improvement was obtained when entering total
concentration and enantiomeric ratio together in the
model.
Figure 3 illustrates the performance of the model
including total concentration as a covariable. Figure 3
(upper part) shows individual model-predicted MADRS
versus time curves in patients with persistent response,
together with mean population prediction. Upward
curvature of predicted curves between day 21 and
day 28 was present in 11 of 19 patients, suggesting
limitations of the quadratic model in some situations.
Plots of predicted and observed depression scores versus
time for each individual patient indicated that the model
adequately described time dependence in a majority of
cases (n=14, 73.7%), whereas goodness-of-ﬁt was of a
lesser quality in patients with early, abrupt decrease,
Table 3 Models for depression severity versus time curves and relationship to concentration in patients with persistent response to
venlafaxine 300 mg/day (n=19 patients, N=133 data). V venlafaxine, ODV O-desmethylvenlafaxine, SD standard deviation, MADRS
Montgomery and A˚sberg Depression Rating Scale [31]
Parameter estimatea Random eﬀects
model 1 without
covariate
Mixed eﬀects model 2
including covariate
X=log10(V+ODV/median)
Mixed eﬀects model 3
including covariate
X=log10(V+/V))
Mean (a) 34.1 34.1 34.1
Interindividual variability, SD (a) 4.9 4.9 4.9
Mean (b) )2.22 )2.27 )2.35
Interindividual variability, SD (b) 1.00 0.68 0.81
Covariate eﬀect b )3.98 3.58
Mean (c) 0.046 0.048 0.051
Interindividual variability, SD (c) 0.039 0.028 0.032
Covariate eﬀect c 0.154 )0.133
Residual variability, SD () 4.6 4.6 4.6
)2 Log-Likelihood 852.8 843.9 846.6
P valueb 0.012 0.046
aGeneral model for MADRS depression score of patient i at time t was MADRSit=ai+(bi+bX)t+(ci+cX)t
2+it
bLikelihood ratio test for improved goodness of ﬁt with respect to model 1, with two degrees of freedom
Fig. 2 Relationship between slope of Montgomery and A˚sberg
Depression Rating Scale versus time curve and potential covariates
in 19 patients with persistent response to venlafaxine 300 mg/day.
Individual Bayesian estimates of slope were obtained from a
random eﬀects model (model 1 in Table 3). Candidate covariables
were total V+ODV concentration (rS=)0.50, P<0.05, upper part)
and V+/V) enantiomeric ratio (rS=0.55, P<0.05, lower part)
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followed by close to constant MADRS score (n=5). The
distribution of residual errors for each patient is
depicted in Fig. 3 (lower part). Median deviation be-
tween observation and prediction was below 2.5
MADRS points in all subjects. Additional residual plots
and statistics did not reveal any major departure from
the hypotheses underlying linear models. Interestingly,
residuals did not display any signiﬁcant serial correla-
tion across time, suggesting that an autocorrelated error
structure was not needed in the model.
Discussion
In view of accumulating evidence of V early onset of
action [11, 12, 13] and renewed interest in its dual
mechanism on 5-HT and NA neurotransmission [9, 18],
the present study oﬀered a double perspective. First,
pattern analysis provided a categorical picture of treat-
ment response and its potential pharmacokinetic deter-
minants. Second, mixed-eﬀects modelling provided a
dimensional perspective to depression severity versus
time curves and their relationship to concentration. To
our knowledge, the relationship between onset of clinical
response and exposure to V and ODV enantiomers had
not been investigated thus far.
Over a 4-week observation period, pattern analysis
indicated absence of a clinically meaningful response in
45.7% and persistent response in 54.3% of patients
prescribed a ﬁxed 300 mg daily dose of V. Onset of
persistent response occurred early, i.e. within the ﬁrst
2 weeks, for 31.4% of patients. With response deﬁned
according to the Clinical Global Impressions scale
(global improvement £ 2), early persistent response was
similarly observed in 20% and 27% of patients at daily
doses of 200 mg and 375 mg, respectively [11]. When
comparing patients with persistent response to those
with transient or no response, the absence of any
signiﬁcant diﬀerence with respect to V, ODV, V+ODV
and enantiomeric ratios suggested that lack of response
over the ﬁrst 4 weeks of treatment may not depend on
pharmacokinetic factors. Among possible predictors of
inadequate response—misdiagnosis, psychiatric and
medical comorbidity, family history of aﬀective disor-
ders, number of previous episodes, duration of depres-
sion prior to treatment, negative life events and poor
social support—have been invoked [38]. The observation
that 62.5% of patients with non-response or transient
response had received prior antidepressant treatment
suggested that some of them might have been treatment
resistant. The limited duration of the present study,
nevertheless, prevented any conclusion with respect to
further clinical improvement from continuation treat-
ment. In drug-resistant major depression, a slight but
signiﬁcant beneﬁt was obtained from continuing
treatment after an initial 8-week period [39].
As pointed out by Laska [40], time to response only
carries relevance for those patients who respond. It was,
thus, recommended that studies on onset of response
should focus on treatment responders [37]. In the present
study, comparison of patients showing early and delayed
persistent response revealed diﬀerences with respect to
exposure to total V+ODV concentration, with higher
concentration signiﬁcantly associated with early
response. Analysis of depression severity versus time
curves through mixed-eﬀects modelling conﬁrmed that
V+ODV concentration was a signiﬁcant determinant of
the slope describing early improvement. These results
complemented dose-ranging studies suggesting earlier
onset of response at higher doses [4, 5]. Whereas sig-
niﬁcant positive associations between higher plasma
levels and larger decrease of depression score have been
reported [24, 26], studies have focused on endpoint
analysis without considering the time factor to onset of
response. The observed relationship between concen-
tration and time course of clinical improvement in
patients with persistent response also corroborated ear-
lier studies, showing that a persistent course more likely
resulted from true drug eﬀect. Alternatively, non-
persistent response reﬂected non-speciﬁc placebo eﬀect,
Fig. 3 Mixed-eﬀects modelling of Montgomery and A˚sberg
Depression Rating Scale versus time curves, integrating V+ODV
concentration as a covariate, in 19 patients with persistent response
to venlafaxine 300 mg/day (model 2 in Table 3). Population
prediction (thick line) and post-hoc individual predictions (thin
lines) are illustrated in the upper part. Distribution of residuals (i.e.
observed score-predicted score) is illustrated in the lower part as a
series of box plots for each individual patient
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associated with increased relapse rate on continuation
treatment [41].
In the present study, a lower V(+)/V()) ratio was
also signiﬁcantly associated with a shorter time to onset
of persistent response. Again, dimensional analysis of
depression severity versus time curves conﬁrmed that
lower enantiomeric ratio was signiﬁcantly associated
with larger decrease of MADRS score over the initial
period of treatment. Due to the diﬀerent pharmacolog-
ical properties of V enantiomers, patients with decreased
V(+)/V()) ratio may be exposed to a therapeutic moiety
with increased noradrenergic activity [21]. Results, thus,
tend to support the hypothesis that dual 5-HT and NA
reuptake inhibition may be a key factor for early onset
of clinical response [18]. Earlier investigation of phar-
macokinetic variability in the same patients had shown
that reduced V(+)/V()) ratio was associated with re-
duced metabolism of the V()) but not V(+) enantiomer
[23]. It was recently conﬁrmed that CYP2D6 isoenzyme
displays marked stereoselectivity towards the ()) enan-
tiomer, with poor metabolism and administration of
CYP2D6 inhibitors associated with decreased V(+)/
V()) ratio [22]. Whereas decreased CYP2D6 activity
may be associated with cardiovascular toxicity [42], its
potential role with respect to onset of response to V
remains to be investigated.
As methodological issues have been at the centre of
the debate on onset of action, qualities and limitations of
the present study require careful consideration. Several
criteria generally required for investigating the time
factor in response to antidepressant drugs were met in
the present study. Persistent response, deﬁned as a 50%
decrease from baseline depression score, sustained over
time, fulﬁlled the need for a widely accepted, clinically
meaningful deﬁnition [35]. The ﬁxed 300-mg daily dose
achieved early and the bi-weekly clinical assessments
over the initial phase of treatment were in keeping with
recommendations [17]. The use of two statistical ap-
proaches provided complementary categorical and
dimensional perspectives, which both proved their value
in documenting onset of response to antidepressant
treatment. In particular, mixed-eﬀects models have been
recently advocated [16]. With the focus being placed on
the individual patient, they allow for the presence of
missing data, constant or time-varying covariates and
autocorrelated error structure [36]. Finally, plasma levels
rather than daily doses served as indicators of actual
exposure to drug and repeated measurements on day 14
and day 28 limited the possible inﬂuence of uncontrolled
intra-individual variability factors, such as erratic
compliance [23].
Among the weaknesses of the study, small sample size
obviously limited its power to study the interplay of
potentially inﬂuent factors and its external validity,
prompting for replication. In particular, the respective
roles of total concentration and/or enantiomeric ratio
remain to be investigated in a larger population. Other
diﬃculties arose from the naturalistic design of the
study, which did not include a washout period and
allowed for comedication with hypnotics, tranquillisers
and low-dose trazodone during the study. V exerts a
marked eﬀect on sleep architecture, so that hypnotics or
low-dose trazodone are commonly coprescribed at ini-
tiation of therapy [43]. However, it cannot be excluded
that part of the observed eﬀect might be attributed to
pre-study medication or to comedication on speciﬁc
components of depression, such as sleep or anxiety.
Additionally, a possible role of comedication prescribed
for somatic disorders cannot be excluded. Another issue
is the 4-week duration of the present study, dictated by
its primary focus on a lithium augmentation strategy
from day 28. In clinical trials of antidepressants [44],
4 weeks is generally considered too short, but believed to
provide an adequate time frame to dictate changes in
therapeutic strategies in the absence of minimal
improvement over that period [38]. In the present study,
a majority of patients with persistent response (n=12,
63.2%) displayed minimal change of depression score
between day 21 and day 28 (MADRS diﬀerence £ 2).
The predictive value of sustained response over the ﬁrst
4 weeks of treatment remains to be assessed with respect
to response on continuation treatment.
Keeping in mind its preliminary nature, the present
study extended previous dose–response studies by doc-
umenting earlier response to venlafaxine associated with
higher V+ODV concentration in patients at a ﬁxed 300-
mg daily dose. It raised the hypothesis that increased
exposure to the more noradrenergic V()) enantiomer
may be relevant to early improvement of depression.
The need for replication studies is further prompted by
renewed interest for the role of noradrenaline in
depression and onset of response in particular. Nor-
adrenaline appears to have a signiﬁcant role in social
functioning by improving energy and motivation [45],
leading to postulate diﬀerent time courses for the
diﬀerent components of depression [17].
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